Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2+ Metastatic Breast Cancer
NCT02562378Phase 1Completed
- Sponsor
- MEDSIR
- Start
- Oct 2015
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab emtansine and non-pegylated liposomal doxorubicin in breast cancer, sponsored by MEDSIR. Primary endpoints: Hematological - Dose Limiting Toxicities at 6 weeks and Non-Hematological - Dose Limiting Toxicities at 6 weeks. Started Oct 2015; status: completed.
02
Drugs
trastuzumab emtansinenon-pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02562378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562378.